Role of gemcitabine in breast cancer management: An update

Baldeep Wirk, Edith Perez

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Anthracyclines and the taxanes are now used earlier in the course of therapy for metastatic breast cancer, and increasingly as part of adjuvant treatment. Accordingly, novel therapies are warranted, including alternatives to anthracyclines and combination strategies in the setting of disease resistance to or disease progression after anthracycline and taxane therapy. Gemcitabine is part of this strategy. The gemcitabine/paclitaxel combination has emerged as part of a new standard of combination therapy for advanced breast cancer, based on phase III data showing superiority of this combination over paclitaxel alone in the first-line therapy setting. Gemcitabine alone, or in combination with paclitaxel and other agents, is also undergoing evaluation in other settings including the refractory metastatic setting, as part of management of patients with HER2-positive disease, and also as part of adjuvant therapy for breast cancer.

Original languageEnglish (US)
Pages (from-to)6-14
Number of pages9
JournalSeminars in oncology
Volume33
Issue numberSUPPL. 2
DOIs
StatePublished - Jan 1 2006

Fingerprint

gemcitabine
Breast Neoplasms
Anthracyclines
Paclitaxel
Therapeutics
Taxoids
Disease Resistance
Disease Progression

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Wirk, Baldeep ; Perez, Edith. / Role of gemcitabine in breast cancer management : An update. In: Seminars in oncology. 2006 ; Vol. 33, No. SUPPL. 2. pp. 6-14.
@article{3297813688d84e5ab8822238e7738365,
title = "Role of gemcitabine in breast cancer management: An update",
abstract = "Anthracyclines and the taxanes are now used earlier in the course of therapy for metastatic breast cancer, and increasingly as part of adjuvant treatment. Accordingly, novel therapies are warranted, including alternatives to anthracyclines and combination strategies in the setting of disease resistance to or disease progression after anthracycline and taxane therapy. Gemcitabine is part of this strategy. The gemcitabine/paclitaxel combination has emerged as part of a new standard of combination therapy for advanced breast cancer, based on phase III data showing superiority of this combination over paclitaxel alone in the first-line therapy setting. Gemcitabine alone, or in combination with paclitaxel and other agents, is also undergoing evaluation in other settings including the refractory metastatic setting, as part of management of patients with HER2-positive disease, and also as part of adjuvant therapy for breast cancer.",
author = "Baldeep Wirk and Edith Perez",
year = "2006",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2005.07.028",
language = "English (US)",
volume = "33",
pages = "6--14",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 2",

}

Role of gemcitabine in breast cancer management : An update. / Wirk, Baldeep; Perez, Edith.

In: Seminars in oncology, Vol. 33, No. SUPPL. 2, 01.01.2006, p. 6-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of gemcitabine in breast cancer management

T2 - An update

AU - Wirk, Baldeep

AU - Perez, Edith

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Anthracyclines and the taxanes are now used earlier in the course of therapy for metastatic breast cancer, and increasingly as part of adjuvant treatment. Accordingly, novel therapies are warranted, including alternatives to anthracyclines and combination strategies in the setting of disease resistance to or disease progression after anthracycline and taxane therapy. Gemcitabine is part of this strategy. The gemcitabine/paclitaxel combination has emerged as part of a new standard of combination therapy for advanced breast cancer, based on phase III data showing superiority of this combination over paclitaxel alone in the first-line therapy setting. Gemcitabine alone, or in combination with paclitaxel and other agents, is also undergoing evaluation in other settings including the refractory metastatic setting, as part of management of patients with HER2-positive disease, and also as part of adjuvant therapy for breast cancer.

AB - Anthracyclines and the taxanes are now used earlier in the course of therapy for metastatic breast cancer, and increasingly as part of adjuvant treatment. Accordingly, novel therapies are warranted, including alternatives to anthracyclines and combination strategies in the setting of disease resistance to or disease progression after anthracycline and taxane therapy. Gemcitabine is part of this strategy. The gemcitabine/paclitaxel combination has emerged as part of a new standard of combination therapy for advanced breast cancer, based on phase III data showing superiority of this combination over paclitaxel alone in the first-line therapy setting. Gemcitabine alone, or in combination with paclitaxel and other agents, is also undergoing evaluation in other settings including the refractory metastatic setting, as part of management of patients with HER2-positive disease, and also as part of adjuvant therapy for breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=32044433992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044433992&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2005.07.028

DO - 10.1053/j.seminoncol.2005.07.028

M3 - Article

C2 - 16472712

AN - SCOPUS:32044433992

VL - 33

SP - 6

EP - 14

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 2

ER -